At Biopôle since 2012.
Med Discovery is a Swiss biopharmaceutical company dedicated to the discovery and the development of highly specific treatments for uro-genital cancers. Med Discovery develops protein-based drugs based on the optimization of natural proteins involved in the regulation of biological pathways. To achieve our goals, we are leveraging a unique in-house expertise in kallikreins, the biggest class of human proteases, combined with an international network in clinical urology.
Med Discovery’s lead compound for prostate cancer is currently entering clinical phase I trials. Our business model is the clinical development and validation of this innovative drug MDPK67b until Phase II (clinical efficacy) in prostate cancer.
Using this approach, Med Discovery intends to become a leading research and development biotech company in the uro-genital field, developing products both in-house and with appropriate partners.